KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Work In Process (2016 - 2021)

Historic Work In Process for Biomarin Pharmaceutical (BMRN) over the last 12 years, with Q3 2021 value amounting to $412.4 million.

  • Biomarin Pharmaceutical's Work In Process rose 3901.41% to $412.4 million in Q3 2021 from the same period last year, while for Sep 2021 it was $412.4 million, marking a year-over-year increase of 3901.41%. This contributed to the annual value of $308.3 million for FY2020, which is 1191.27% down from last year.
  • According to the latest figures from Q3 2021, Biomarin Pharmaceutical's Work In Process is $412.4 million, which was up 3901.41% from $374.0 million recorded in Q2 2021.
  • In the past 5 years, Biomarin Pharmaceutical's Work In Process registered a high of $412.4 million during Q3 2021, and its lowest value of $194.6 million during Q1 2018.
  • In the last 5 years, Biomarin Pharmaceutical's Work In Process had a median value of $296.7 million in 2020 and averaged $295.3 million.
  • Per our database at Business Quant, Biomarin Pharmaceutical's Work In Process skyrocketed by 5146.37% in 2019 and then tumbled by 1191.27% in 2020.
  • Quarter analysis of 5 years shows Biomarin Pharmaceutical's Work In Process stood at $234.7 million in 2017, then fell by 1.54% to $231.1 million in 2018, then soared by 51.46% to $350.0 million in 2019, then dropped by 11.91% to $308.3 million in 2020, then surged by 33.78% to $412.4 million in 2021.
  • Its Work In Process stands at $412.4 million for Q3 2021, versus $374.0 million for Q2 2021 and $355.8 million for Q1 2021.